ERBB2 and neoplasm: For MBCs with TMB of at least ten mutations per megabase, representing the current indication for the tumor agnostic use of anti-programmed death-1 (anti-PD-1) immunotherapy32, APOBEC3 constituted the dominant mutational process in most HR+/HER2− and HR+/HER2+ tumors (Fig. 1e).